Efficacy of adalimumab in Behçet's disease. Description of 6 cases;Eficacia del adalimumab en la enfermedad de Behçet: descripción de 6 casos

Reumatologia Clinica

Volumn 7, Issue 4, 2011, Pages 258-261

  Calvo Catalá, Javier ^a   Campos Fernández, Cristina ^a   Rueda Cid, Amalia ^a   González Cruz Cervellera, María Isabel ^a   Baixauli Rubio, Aurelio ^b   Pastor Cubillo, María Dolores ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Adalimumab; Anti TNF; Beh et's disease; Uveitis

Indexed keywords

ADALIMUMAB; INFLIXIMAB;

ABSENCE OF SIDE EFFECTS; ARTICLE; BEHCET DISEASE; DISEASE CONTROL; DRUG EFFICACY; DRUG RESPONSE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; BEHCET SYNDROME; FEMALE; HUMANS; MALE; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79959283603     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: 10.1016/j.reuma.2010.10.003     Document Type: Article

References (20)

1. Yazici H., Tüzün Y., Pazarli H., Yurdakul S., Ozyazgan Y., Ozdoĝan H., et al. Influence of age of onset and patient's sex on the prevalence and severity of manifestations of Behçet's syndrome. Ann Rheum Dis 1984, 43:783-789.
2. Kural-Seyahi E., Fresko I., Seyahi N., Ozyazgan Y., Mat C., Hamuryudan V., et al. The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 2003, 82:60-76.
3. Chan A.T., Flossmann O., Mukhtyar C., Jayne D.R., Luqmani R.A. The role of biologic therapies in the management of systemic vasculitis. Autoimmun Rev 2006, 5:273-278.
4. Mushtaq B., Saeed T., Situnayake R.D., Murray P.I. Adalimumab for sight-threatening uveitis in Behçet's disease. Eye 2007, 21:824-825.
5. Callejas-Rubio J.L., Sánchez-Cano D., Ríos-Férnandez R., Ortego-Centeno N. Treatment of Behçet's disease with adalimumab. Med Clin (Barc) 2008, 131:438-439.
6. Belzunegui J., López L., Paniagua I., Intxausti J.J., Maíz O. Efficacy of infliximab and adalimumab in the treatment of a patient with severe neuro-Behçet's disease. Clin Exp Rheumatol 2008, 26(4 Suppl 50):S133-S134.
7. Yildiz N, Alkan H, Ardic F, Topuz O. Successful treatment with adalimumab in a patient with coexisting Behçet's disease and ankylosing spondylitis. Rheumatol Int. Published online 2010 march 30.
8. Lee S.W., Lee S.Y., Kim K.N., Jung J.K., Chung W.T. Adalimumab treatment for life threatening pulmonary artery aneurysm in Behçet disease: a case report. Clin Rheumatol 2010, 29:91-93.
9. Ariyachaipanich A., Berkelhammer C., Nicola H. Intestinal Behçet's disease: Maintenance of remission with adalimumab monotherapy. Inflamm Bowel Dis 2009, 15:1769-1771.
10. Takase K., Ohno S., Ideguchi H., Uchio E., Takeno M., Ishigatsubo Y. Successful switching to adalimumab in an infliximab-allergic patient with severe Behçet disease-related uveitis. Rheumatol Int Published online 2009, (Oct 9).
11. Olivieri I., D'Angelo S., Padula A., Leccese P., Mennillo G.A. Successful treatment of recalcitrant genital ulcers of Behçet's disease with adalimumab after failure of infliximab and etanercept. Clin Exp Rheumatol 2009, 27(2 Suppl 53):S112.
12. van Laar J.A., Missotten T., van Daele P.L., Jamnitski A., Baarsma G.S., van Hagen P.M. Adalimumab: a new modality for Behçet's disease?. Ann Rheum Dis 2007, 66:565-566.
13. Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease [no authors listed]. Lancet. 1990; 335:1078-1080.
14. Rodríguez-Valverde V., Cáliz Cáliz R., Álvaro-Gracia Álvaro J.M., Marenco de la Fuente J.L., Mulero Mendoza J., Tornero Molina J., et al. III Actualización del Consenso de la Sociedad Española de Reumatología sobre terapia biológica en la artritis reumatoide. Reumatol Clin 2006, 2(Suppl 2):S52-S59.
15. Turan B., Gallati H., Erdi H., Gürler A., Michel B.A., Villiger P.M. Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Behçet's disease; soluble TNFR-75 as a biological marker of disease activity. J Rheumatol 1997, 24:128-132.
16. Verjans G.M., van Hagen P.M., van der Kooi A., Osterhaus A.D., Baarsma G.S. Vgamma9Vdelta2 T cells recovered from eyes of patients with Behcet's disease recognize non-peptide prenyl pyrophosphate antigens. J Neuroimmunol 2002, 130:46-54.
17. Evereklioglu C. Current concepts in the etiology and treatment of behcet disease. Surv Ophthalmol 2005, 50:297-350.
18. Sfikakis P.P., Markomichelakis N., Alpsoy E., Assaad-Khalil S., Bodaghi B., Gul A., et al. Anti-TNF therapy in the management of Behçet's disease-review and basis for recommendations. Rheumatology 2007, 46:736-741.
19. Hatemi G., Silman A., Bang D., Bodaghi B., Chamberlain A.M., Gul A., et al. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis 2008, 67:1656-1662. EULAR Expert Committee.
20. Hatemi G., Silman A., Bang D., Bodaghi B., Chamberlain A.M., Gul A., Houman M.H., et al. Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease. Ann Rheum Dis 2009, 68:1528-1534.